Global Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, & Forecasts, 2026

Description

List of Tables

Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified and explained, new drugs identified by iPSC screens are in the pipeline, and clinical trials employing human iPSC-derived cell types have been undertaken. iPSCs can be used to explore the causes of disease onset and progression, create and test new drugs and therapies, and treat previously incurable diseases.

Today, methods of commercializing induced pluripotent stem cells (iPSCs) include:

Cellular Therapy: iPSCs are being investigated for use in a wide range of cell therapy applications aimed at reversing injuries or curing diseases by replacing damaged or lost cells.
Disease Modeling: iPSCs derived from patients with specific disorders can be differentiated into disease-specific cell types, enabling the creation of accurate, functional disease models "in a dish" for research and therapeutic development.
Drug Development and Discovery: iPSCs provide physiologically relevant cells for drug discovery processes, including compound identification, target validation, compound screening, and tool development, significantly improving the efficiency and relevance of these efforts.
Personalized Medicine: By combining iPSCs with genome-editing technologies like CRISPR, scientists can introduce precise genetic modifications, such as knock-outs, knock-ins, or single base changes, paving the way for customized treatments tailored to individual genetic profiles.
Toxicology Testing: iPSCs or their derivatives (tissue-specific cells) are used for toxicology screening to assess the safety and efficacy of compounds or drugs in living cells, reducing reliance on animal testing.
Tissue Engineering: iPSCs can be cultured on biocompatible scaffolds that mimic the structure and properties of target tissues, providing a supportive environment for cell growth and differentiation and aiding the development of engineered tissues for transplantation.
Organoid Production: iPSCs can self-organize into 3D structures called organoids, which closely resemble the structure and function of human organs. Organoids are valuable for studying organ development, modeling diseases, and testing drug candidates.
Gene Editing: iPSCs can be modified using techniques like CRISPR-Cas9 to correct disease-causing mutations or introduce specific genetic alterations. These edited iPSCs can then be differentiated into functional cells for transplantation or advanced disease studies.
Research Tools: iPSCs and their derivatives are extensively used in both basic and applied research to study cellular processes, understand diseases, and test experimental therapies.
Stem Cell Banking: iPSC repositories store and provide access to diverse iPSC-derived cell types, offering researchers valuable resources to investigate conditions using cells from both healthy and affected donors.
Cultured Meat Production: iPSCs are utilized in lab-grown meat production, serving as a cellular foundation for creating clean, sustainable meat products without the need for traditional animal farming.
3D Bioprinting: iPSCs can be differentiated into specific cell types, such as skin, heart, or liver cells, and incorporated into bioinks for use in 3D bioprinting applications, enabling the creation of complex tissue structures.

iPSC Market Dynamics

Since the discovery of iPSCs approximately 18 years ago, the field has advanced at an unprecedented pace. It took just seven years for the first iPSC-derived cell product to be transplanted into a human patient in 2013. Since then, iPSC-derived cells have been increasingly used in preclinical studies, physician-led research, and clinical trials worldwide, underscoring their transformative potential.

The discovery of iPSCs has revolutionized several scientific fields, including drug discovery, toxicity testing, and in-a-dish disease modeling, while also having a profound impact on cell and gene therapy. Their ability to multiply indefinitely in vitro and differentiate into specialized cells has made them a highly versatile and ideal source for clinical cell replacement therapies and advanced disease modeling.

The first cellular therapy involving iPSCs began in 2013 at the RIKEN Center in Kobe, Japan. Led by Dr. Masayo Takahashi, this trial investigated the safety of iPSC-derived retinal cell sheets in patients with macular degeneration. In 2016, Cynata Therapeutics achieved a world first by gaining approval for a clinical trial of an allogeneic iPSC-derived cell product, CYP-001, for treating steroid-resistant acute graft-versus-host disease (GvHD). This iPSC-derived mesenchymal stem cell (MSC) product demonstrated positive safety and efficacy results, successfully meeting its clinical endpoints.

Today, iPSCs are at the center of at least 228 ongoing clinical trials targeting a range of conditions. iPSC-derived MSCs are being tested for steroid-resistant acute GvHD, while dopaminergic progenitors derived from iPSCs are being evaluated for Parkinson’s disease. In oncology, iPSC-derived natural killer (iNK) cells are being studied as cancer immunotherapies for metastatic solid tumors. Other applications include the use of retinal pigment epithelial cells for age-related macular degeneration (AMD) and insulin-secreting beta cells derived from iPSCs for Type 1 diabetes. These diverse therapeutic programs highlight the vast potential of iPSCs in treating a variety of diseases.

Of the 228 total trials, 66 are specifically evaluating iPSC-derived cells as therapeutics - the rest are non-therapeutic, such as disease modeling a research use - with a focus on regenerative medicine applications like Parkinson's disease, retinal diseases, heart failure, and immune disorders, mostly in Phase I/II.

The iPS cell sector has seen steady M&A activity in recent years, including Axol Biosciences' acquisitions of Newcells Biotech and Phenocell, and Century Therapeutics' $35 million acquisition of Clade Therapeutics, alongside a wave of strategic partnerships and licensing deals aimed at scaling GMP-compliant manufacturing and advancing off-the-shelf allogeneic cell therapies. Venture capital investment has remained strong, totaling roughly $1.04 billion between 2023 and April 2026, down from a 2021 peak of $2.15 billion, as investors increasingly favor companies with proprietary, full-stack manufacturing platforms poised to move from research into clinical-stage therapeutics.

The commercial potential of iPSCs has also expanded significantly. Companies are leveraging iPSC-derived products in drug development, disease modeling, and toxicology testing. FUJIFILM Cellular Dynamics International (FCDI) stands out as one of the largest players in the field. Cellular Dynamics International (CDI), founded in 2004 by Dr. James Thomson at the University of Wisconsin-Madison, became one of the first companies to derive human iPSC lines in 2007. In 2015, FUJIFILM acquired CDI for $307 million, creating FCDI, which is now the world’s largest producer of human cells derived from iPSCs for research and regenerative medicine.

ReproCELL, founded in 2009 as a venture from the University of Tokyo and Kyoto University, was the first company to commercialize iPSC products. Its ReproCardio line of iPSC-derived cardiomyocytes paved the way for the industry. In Europe, leading competitors include Evotec and Ncardia. Evotec, based in Hamburg, Germany, has built one of the most advanced iPSC platforms in the world, focusing on industrializing iPSC-based drug screening. Ncardia, formed through the merger of Axiogenesis and Pluriomics in 2017, specializes in cardiac and neural applications of iPSCs. Axiogenesis, one of its predecessors, was the first European company to license iPSC technology in 2010.

Large research supply companies are also playing a major role in the commercialization of iPSC-derived products. These include Lonza, BD Biosciences, Thermo Fisher Scientific, Merck, Takara Bio, and numerous others. Collectively, more than 90 companies are active in the iPSC market, offering a broad range of products, services, and technologies that cater to both research and therapeutic applications.

The global iPSC market continues to grow rapidly. A comprehensive report on the field provides an overview of key players, strategic partnerships, and innovations driving the sector. The report explores the current status of iPSC research, manufacturing technologies, and clinical developments. It highlights the rates of iPSC-related patents, publications, and trials, detailing all known therapeutic programs involving iPSC-derived cells. Additionally, the report covers the funding landscape, examining fundraising efforts, IPOs, and co-development agreements that are shaping the market’s trajectory.

The report also delves into the expanding use of iPSCs in drug discovery and the strategic partnerships that are driving growth in this sector. It presents a detailed breakdown of market size by application, technology, cell type, and geography (North America, Europe, Asia-Pacific, and the rest of the world). Total market size figures, along with projected growth rates through 2034, provide insights into the future of the iPSC industry.

With their remarkable versatility, iPSCs are set to redefine medicine and biotechnology. From disease modeling and drug discovery to advanced cell replacement therapies, iPSCs are driving innovation at every level. As companies continue to refine manufacturing technologies and expand therapeutic applications, the future of iPSCs holds immense promise for transforming healthcare and scientific research.

About the Publisher

With an online readership of nearly one million viewers per year, the publisher is a U.S. market research firm founded in 2006 that has over 20+ years of experience in tracking stem cell markets. As the first and only market research firm to specialize in the stem cell industry, the publisher’s research has been cited by the Wall Street Journal and Vogue Magazine, as well as quoted in Tony Robbin’s best-selling book, Life Force. Founded in 2006 and headquartered in Washington, DC, the publisher is strategically positioned to be near the National Institutes of Health (NIH), the U.S. FDA, the Maryland Biotech Corridor, and policy makers on Capitol Hill. In addition to leveraging an experienced team of analysts, the publisher has unparalleled access to key opinion leaders (KOLs) from across the global iPSC market.

1. REPORT OVERVIEW

1.1 Statement of the Report

2. INTRODUCTION

3. CURRENT STATUS OF IPSC INDUSTRY

3.1 Approval of the First Two iPSC-based Therapies
- 3.1.1 Amchepry (raguneprocel)
- 3.1.2 ReHeart
3.2 Forthcoming iPSC-Derived Therapeutics
- 3.2.1 Fertilo
- 3.2.2 Bemdaneprocel (BRTX-100)
3.3 The Second Line of iPSC-based Products in Clinical Trials
3.4 Current Status of iPSC-Based Clinical Trials for Therapeutic Development
3.5 AI-Powered Automation in iPSC Manufacturing
- 3.5.1 Companies Providing AI-Powered Automation Services
3.6 Advanced Reprogramming Technologies Currently in use
- 3.6.1 The Major Patent Cliff beginning in
  - 3.6.1.1 The New “Post-Expiry” Opportunities
3.7 Shift toward Automation in iPSC Production
3.8 Current Utilization of Genome-Editing Tools in iPSCs
3.9 Current Utilization of Organoids & 3D Tissues in iPSC-Derived Disease Models
3.10 Significant increase in the number of Market Participants
- 3.10.1 Types of iPSC-Related Companies in
  - 3.10.1.1 The iPSC Therapeutics Developers (Clinical & Preclinical) Companies
  - 3.10.1.2 iPSC Product & Research Tool Suppliers
  - 3.10.1.3 Contract Development and Manufacturing Organizations (CDMOs)
  - 3.10.1.4 Longevity and Rejuvenation Companies (Partial Reprogramming)

4. IPSC MANUFACTURING

4.1 Tissue Acquisition and Donor Screening
4.2 Somatic Cell Isolation and Priming
- 4.2.1 Isolation of Dermal Fibroblasts
4.3 Reprogramming of Somatic Cells into iPSCs
4.4 Expansion and Selection of iPSC Colonies
- 4.4.1 Selection of iPSC Colonies after Reprogramming
4.5 Directed Differentiation of iPSCs into Specific Cell Types
4.6 Development of Organoids from iPSCs
- 4.6.1 Key Steps in iPSC-Derived Organoid Development

5. RESEARCH PUBLICATIONS ON INDUCED PLURIPOTENT STEM CELLS

5.1 Rapid Growth of iPSC Publications in PubMed.gov
5.2 Categories of iPSC Research Themes
- 5.2.1 PubMed Published iPSC Papers on Pathophysiological Studies
- 5.2.2 PubMed Published iPSC Papers on Reprogramming Studies
- 5.2.3 PubMed Published Papers on iPSC Differentiation Studies
- 5.2.4 PubMed Published Papers on iPSC-based Drug Discovery
- 5.2.5 PubMed Published Papers on iPSC-based Cell Therapy
- 5.2.6 Future Trends in iPSC Research
  - 5.2.6.1 Anticipated advancements in Therapeutic Applications
  - 5.2.6.2 Enhanced Disease Modeling and Drug discovery
  - 5.2.6.3 Technological Innovations and Automation
  - 5.2.6.4 Future Research Directions and Challenges

6. IPSC PATENT LANDSCAPE

6.1 iPSC Patent Applications by Jurisdiction
6.2 iPSC Patent Applicants
6.3 Inventors of iPSC Patent Applications
6.4 Major iPSC Patent Owners
6.5 Current Legal Status of iPSC Patents
- 6.5.1 Granted iPSC Patents
- 6.5.2 Key Technology Areas Protected
- 6.5.3 Geographical Trends in iPSC Granted Patents
- 6.5.4 Recently Granted iPSC Patents (2024-2026)
  - 6.5.4.1 Recent Patent of RxCell, Inc.
  - 6.5.4.2 Recent Patent of Pluristyx
  - 6.5.4.3 Recent Patent of Applied StemCell, Inc.
  - 6.5.4.4 Recent Patent of iPS Academia Japan/Kyoto University
  - 6.5.4.5 Recent Patent of Allele Biotechnology
6.6 Recent iPSC Patent Licensing Activity
- 6.6.1 Licensing Fees for iPSC Patents
6.7 The Future Direction of Growth in iPSC Patent Activity
- 6.7.1 The “Patent Cliff” and Focus Shift

7. CLINICAL TRIAL LANDSCAPE: INDUCED PLURIPOTENT STEM CELLS

7.1 Late-Stage iPSC Clinical Trials & Progress
7.2 Current Recruitment Status
7.3 iPSC Clinical Trials by Study Designs
7.4 Therapeutic & Non-Therapeutic iPSC Clinical Trials
- 7.4.1 The iPSC Non-Therapeutic Clinical Studies by Use
- 7.4.2 Diseases Targeted by Therapeutic Studies
- 7.4.3 The iPSC Clinical Trials Addressing Ocular Diseases
- 7.4.4 Trials IPSC-Based Clinical Trials Addressing CNS Disorders
- 7.4.5 IPSC-Derived Cardiomyocytes and Muscle Products in Clinical Trials
- 7.4.6 IPSC-Based in Immune and Blood Products Clinical Trials
- 7.4.7 Stromal Products in Clinical Trials
7.5 iPSC-based Clinical Trials by Phase of Study
7.6 iPSC Clinical Trials by Funder Type
7.7 Geographic Distribution of iPSC Clinical Trials
7.8 Predicted Future Directions of iPSC-Based Clinical Trials

8. M&A, COLLABORATIONS AND FUNDING ACTIVITIES IN IPSC SECTOR

8.1 Mergers and Acquisitions (M&A) in iPSC Sector
- 8.1.1 Axol Biosciences’ Acquisition of Newcells Biotech
- 8.1.2 Acquisition of Phenocell by Axol Biosciences
- 8.1.3 Acquisition of Clade Therapeutics by Century Therapeutics
8.2 Partnership/Collaboration & Licensing Deals in iPSC Sector
- 8.2.1 Cartherics & Catalent
- 8.2.2 Applied StemCell, Inc. & Cellipont Bioservices
- 8.2.3 GelMEDIX & Catalent
- 8.2.4 ISCT & JSRM
- 8.2.5 SmartCella Holding & Catalent
- 8.2.6 Mytos & Pluristyx
- 8.2.7 Cell X Technologies & BioLamina
- 8.2.8 Pluristyx & Solesis
- 8.2.9 Pluristyx & BioLamia
- 8.2.10 Celaid Therapeutics & AGC
- 8.2.11 Cellino & Karis Bio
- 8.2.12 Ginkgo Bioworks & Universal Cells
- 8.2.13 BrightPath Bio & Cellistic
- 8.2.14 Alloy Therapeutics & Takeda
- 8.2.15 Factor Bioscience & Eterna Therapeutics
- 8.2.16 Aspen Neuroscience & Cell X Technologies
- 8.2.17 Shinobi Therapeutics & Panasonic
- 8.2.18 SCG Cell Therapy and A*STAR
- 8.2.19 Charles River Laboratories & Pluristyx
- 8.2.20 Pluristyx & National Resilience, Inc
- 8.2.21 University of Texas & GeneCure
- 8.2.22 BlueRock Therapeutics & Bit.bio
- 8.2.23 Applied Stem Cell, Inc. & CIRM
8.3 Venture Capital Funding in iPSC Sector
- 8.3.1 Trailhead Biosystems, Inc.
- 8.3.2 Morphocell Technologies, Inc.
- 8.3.3 Aspen Neuroscience, Inc.
- 8.3.4 Celaid Therapeutics, Inc.
- 8.3.5 GC Therapeutics, Inc.
- 8.3.6 iRegene Therapeutics
- 8.3.7 Gameto
- 8.3.8 Pluristyx
- 8.3.9 Asgard Therapeutics
- 8.3.10 Kenai Therapeutics
- 8.3.11 Pluristyx
- 8.3.12 Fujifilm Cellular Dynamics
- 8.3.13 Mogrify, Ltd.
- 8.3.14 Heartseed, Inc.
- 8.3.15 Elevate Bio

9. GENERATION OF INDUCED PLURIPOTENT STEM CELLS (IPSCS)

9.1 Reprogramming Factors (OSKM Cocktail/Yamanaka Factors)
- 9.1.1 Roles of OSKM Factors in the Induction of iPSCs
- 9.1.2 Companies offering Reprogramming Services
9.2 Direct Reprogramming
- 9.2.1 Companies offering Direct Reprogramming Services
9.3 Delivery of Reprogramming Factors
- 9.3.1 Currently Favored Reprogramming Factors
  - 9.3.1.1 Sendai Virus (SeV) Reprogramming (Gold Standard)
  - 9.3.1.2 mRNA-Based Reprogramming (High Safety)
  - 9.3.1.3 Episomal Plasmid Vectors (Simplicity)
  - 9.3.1.4 Comparative Efficacies of Reprogramming Methods
9.4 Genome Editing Technologies in iPSC Generation
- 9.4.1 Companies offering CRISPR/Cas9 Services for iPSC Generation
9.5 Development of iPSC-Derived Organoids
- 9.5.1 Companies Developing iPSC-Derived Organoids
9.6 Development of iPSC-Derived Cardiac Tissue Sheets
9.7 Development of iPSC-Derived RPE Sheets
10.1 EBiSC
- 10.1.1 IPSCs Available with EBiSC
10.2 RIKEN BRC
- 10.2.1 The iPSC Lines available with RIKEN BRC
10.3 CiRA
10.4 WiCell
10.5 HipSci
10.6 hPSCreg
10.7 inStem
10.8 Coriell Institute for Medical Research
- 10.8.1 Cell Lines offered by Coriell
10.9 Cost Difference for iPSC Lines between Non-Profit Banks and Commercial Providers
10.10 Cell Sources & Reprogramming Methods in iPSC Banks
10.11 Ownership and Funding for iPSC Banks
11.1 Applications of iPSCs in Basic Research
- 11.1.1 Consumption of iPSC lines in Research
- 11.1.2 Providers of iPSC Research Products for Researchers
- 11.1.3 Product Categories used in iPSC Research
  - 11.1.3.1 The iPSC Reprogramming Kits
  - 11.1.3.2 Culture Media & Reagents used in Research
  - 11.1.3.3 Differentiated iPS Cells used in Research
  - 11.1.3.4 3D Organoids from iPSCs for Research
  - 11.1.3.5 Specialized Services in iPSC Manufacturing
  - 11.1.3.6 Procurement of iPSC-based Research Products by Researchers
    - 11.1.3.6.1 Procurement from Commercial Suppliers
    - 11.1.3.6.2 Procurement from Public and Private Repositories
    - 11.1.3.6.3 Direct Generation/Custom Services
11.2 Applications of iPSCs in Drug Discovery
- 11.2.1 Applications of iPSCs in Patient-Specific Disease Modeling
  - 11.2.1.1 Companies offering iPSC-Derived Cardiomyocytes for Drug Discovery
    - 11.2.1.1.1 Drugs Tested for Cardiovascular Diseases using iPSCs
  - 11.2.1.2 Companies offering iPSC-derived Neuronal Cells for Drug Discovery
    - 11.2.1.2.1 Drugs Tested for Neurological Diseases using iPSCs
  - 11.2.1.3 Companies offering iPSC-Derived RPEs
    - 11.2.1.3.1 Drugs Tested for Ocular Diseases using iPSC Lines
  - 11.2.1.4 Companies developing iPSCs to Discover Drugs for Metabolic Diseases
    - 11.2.1.4.1 Drugs Tested in iPSCs for Metabolic Diseases
  - 11.2.1.5 Companies Developing iPSCs to Discover Drugs for Blood Disorders
    - 11.2.1.5.1 Drugs Tested for Blood Disorders using iPSCs
  - 11.2.1.6 The iPSCs in High-Throughput Screening (HTS)
  - 11.2.1.7 The iPSCs in Drug Toxicity and Safety Assessment
    - 11.2.1.7.1 Companies offering Toxicity Testing Services using iPSC-Derived Cells
    - 11.2.1.7.2 Drugs Tested for their Toxicity using iPSC Lines
    - 11.2.1.7.3 Relative Use of iPSC-Derived Cell Types used in Toxicity Testing Studies
  - 11.2.1.8 The iPSCs in Personalized Medicine and Genomic Studies
- 11.2.3 Applications of iPSC-Derived Cells in Cell Therapies (Regenerative Medicine)
  - 11.2.3.1 Companies developing iPSC-based Cell Therapies
  - 11.2.3.2 The Landscape of iPSC-Based Cell Therapy Clinical Trials
    - 11.2.3.2.1 Key Therapeutic Targets in iPSC-Based Cell Therapy Clinical Trials
    - 11.2.3.2.2 iPSC-Based Cell Therapy Clinical Trials
- 11.2.4 Other Novel Applications of iPSCs
  - 11.2.4.1 Bioinks for Tissue Engineering
    - 11.2.4.1.1 Companies developing iPSC-Based Bioinks
  - 11.2.4.2 The iPSCs in the Conservation of Endangered Species
    - 11.2.4.2.1 Key Applications of iPSCs Conservation
    - 11.2.4.2.2 Major Conservation Programs using iPSCs
    - 11.2.4.2.3 Development of iPSCs from Domestic & Wild Animals
  - 11.2.4.3 Cultured Meat Production using iPSCs
    - 11.2.4.3.1 Companies Developing Cultured Meat using iPSCs
11.3 Cost of iPSC-Based Products & Services
12.1 Global Market for Induced Pluripotent Stem Cells (iPSCs) by Geography
12.2 Global Market for iPSCs by Market Segments
12.3 Global Market for iPSC-based Reprogramming Technologies
12.4 Global Market for iPSC-Derived Cell Types
12.5 Global Market for Manual & Automated iPSC Production Services
- 12.5.1 Market Share for Key Modules in iPSC Production
- 12.5.2 Market Shares of Products Utilized in iPSC Manufacturing
- 12.5.3 Percent Market Share of iPSC-Derived Cells by End-Use,
12.6 Key iPSC Market Drivers
12.7: Key iPSC Market Restraints
12.8 Predicted Shifts in iPSC market
- 12.8.1 Shift from Research to Clinical Applications
- 12.8.2 Technological Shifts in Production and Quality
- 12.8.3 Application & Therapeutic Shifts
- 12.8.4 Regional & Strategic Shifts
13.1 28bio
- 13.1.1 The Nexon™ platform
- 13.1.2 CNS-3D Technology
- 13.1.3 CNS-3D Organoid Services
- 13.1.4 PNS-3D Organoids
- 13.1.5 PNS-3D Organoid Services
13.2 AcceGen
- 13.2.1 Treatments for Neurodegenerative Diseases with iPSCs
- 13.2.2 AcceGen’s Pipeline
13.3 Accellta, Ltd.
- 13.3.1 Accellta’s Foodtech
- 13.3.2 Accellta’s Biotech Services
- 13.3.3 Accellta’s Core Technology
13.4 Alder Therapeutics
13.5 Aldevron
- 13.5.1 Key Products and Services for iPSC
13.6 Allele Biotechnology
- 13.6.1 mRNA Reprogramming
- 13.6.2 mRNA Differentiation
13.7 Altos Labs
13.8 Applied StemCell, Inc. (ASC)
- 13.8.1 Genome Editing Platforms
- 13.8.2 The iPSC Drug Discovery Platform
- 13.8.3 The iPSC Gene Editing Services
- 13.8.4 The iPSC Differentiation Services
- 13.8.5 The iPSC Generation Services
- 13.8.6 Product Offerings
13.9 Arktus Therapeutics, Co., Ltd.
- 13.9.1 Technologies
13.10 Aspen Neuroscience
- 13.10.1 Autologous Manufacturing Process
- 13.10.2 Aspen’s Clinical Pipeline
13.11 ATCC
- 13.11.1 Product Offerings
13.12 Axxam S.p.A.
- 13.12.1 The iPSC Platform Capabilities
13.13 Axol Bioscience
- 13.13.1 Products
- 13.13.2 Services
- 13.13.3 iPSC-derived Models
13.14 BD Biosciences
- 13.14.1 Key Contributions and Tools
13.15 Bit.bio
- 13.15.1 Products & Services
  - 13.15.1.1 Human iPSC-derived glial cells
13.16 BlueRock Therapeutics
- 13.16.1 BlueRock’s Cell Therapy Programs
  - 13.16.1.1 Neurology Program
  - 13.16.1.2 Ophthalmology Program
13.17 BPS Bioscience
- 13.17.1 Product Offerings
13.18 BrainXell
- 13.18.1 Product Offerings
- 13.18.2 Services Offered
13.19 BrainZell
- 13.19.1 Technology
- 13.19.2 Selection of Source Cells
13.20 BrightPath Biotherapeutics Co., Ltd.
13.21 Cartherics Pty Ltd
- 13.21.1 CTH-401
- 13.21.2 CTH-004
13.22 Catalent, Inc.
- 13.22.1 Services
13.23 Celogics
- 13.23.1 Custom Cardiomyocytes
13.24 Celregen Therapeutics
- 13.24.1 Core Platform Technologies
- 13.24.2 Key iPSC Product Candidates
13.25 Cellectis
- 13.25.1 TALEN® Technology
- 13.25.2 PulseAgile Technology
13.26 CellGenix GmbH
- 13.26.1 Key Contributions
13.27 Cellistic
- 13.27.1 CDMO Services
- 13.27.2 Allo Chassis™ Platform
- 13.27.3 STAR-CRISPR™ Technology
- 13.27.4 Pulse Cell Line Development Platform
- 13.27.5 Cellistic’s Echo Manufacturing Platform
- 13.27.6 GMP Manufacturing
- 13.27.7 ECHO™-NK Platform
- 13.27.8 Echo™-Cardio platform
- 13.27.9 Echo™-Endothelial Platform
- 13.27.10 Echo™-T Platform
13.28 CellSystems GmbH
- 13.28.1 Core Competencies in iPSC Technology
13.29 Cellusion, Inc.
- 13.29.1 CECSI Cells
13.30 Celregen Therapeutics
- 13.30.1 Products in Development
  - 13.30.1.1 Islet Cells
  - 13.30.1.2 The iCEnCs
13.31 Century Therapeutics
- 13.31.1 Century’s Approach
- 13.31.2 Century’s Precision Gene Editing Technology
  - 13.31.2.1 Allo-Evasion™ Technology
- 13.31.3 Century’s Pipeline Overview
13.32 Citius Pharmaceuticals, Inc.
- 13.32.1 Induced Mesenchymal Stem Cells (i-MSCs)
13.33 clock.bio
- 13.33.1 The clock.bio’s Platform
  - 13.33.1.1 The geneAge Atlas of Aging and Rejuvenation Genes
  - 13.33.1.2 The imAge
  - 13.33.1.3 The clinAge Platform
13.34 Creative Medical Technology Holdings, Inc.
- 13.34.1 The iPSCelz® Program
13.35 CUORiPS, Inc
- 13.35.1 Conditional Approval for ReHeart in Japan
  - 13.35.1.1 Treatment Modality for ReHeart
13.36 Curi Bio, Inc.
- 13.36.1 Curi Bio’s Biosystem Platforms
- 13.36.2 3D Engineered Models
- 13.36.3 The Curi Engine™: Custom Services
13.37 Cynata Therapeutics
- 13.37.1 Cymerus™ Technology
- 13.37.2 Clinical Development
13.38 CytoMed Therapeutics Limited
- 13.38.1 iPSC-γδ NKT Cell Technology
13.39 Defined Bioscience, Inc.
- 13.39.1 Products for Disease Modeling
13.40 Editas Medicine
- 13.40.1 Edita’s iPSC Platform
13.41 EditCo Bio, Inc.
- 13.41.1 Services
- 13.41.2 CRISPR Reagents & Kits
13.42 ErneXa Therapeutics
13.43 Esco Lifesciences
- 13.43.1 Key Contributions
13.44 Evotec
- 13.44.1 Services
13.45 Eyestem Research Pvt. Ltd.
- 13.45.1 Eyecyte-RPE™
- 13.45.2 Eyecyte-PRPTM
- 13.45.3 AAV mediated gene augmentation
13.46 Factor Biosynthesis, Inc.
- 13.46.1 The mRNA Reprogramming Technology Platforms
- 13.46.2 UltraSlice™ Gene Editing Technology Platforms
13.47 Fate Therapeutics, Inc.
- 13.47.1 Fate Therapeutics’ iPSCs Platform
- 13.47.2 Fate Therapeutics’ Pipeline Overview
13.48 FUJIFILM Cellular Dynamics
- 13.48.1 Products
- 13.48.2 Custom Services
- 13.48.3 The iPSC CDMO Services
13.49 Gameto, Inc.
- 13.49.1 Gameto’s Science
  - 13.49.1.1 Fertilo
  - 13.49.1.2 Ameno
  - 13.49.1.3 Deovo
13.50 GC Therapeutics
- 13.50.1 TFome™ Platform
13.51 GenScript
- 13.51.1 iPSC-Related Services
- 13.51.2 iPSC-Related Products
13.52 GOLIVER THERAPEUTICS
- 13.52.1 GOLIVER Solution
13.53 Greenstone Biosciences
- 13.53.1 Products
- 13.53.2 Services
13.54 Healios K.K.
13.55 HeartBeat.bio AG
- 13.55.1 Cardioids (Cardiac Organoids)
  - 13.55.1.1 Cardioid Drug Discovery Platform
- 13.55.2 Disease Models
- 13.55.3 Assays
- 13.55.4 Drug Discovery Strategy
13.56 Heartseed, Inc.
- 13.56.1 Remuscularization Technology
- 13.56.2 Cardiomyocyte Spheroid
13.57 Hebecell Corporation
- 13.57.1 ProtoNK™
- 13.57.2 Contract Manufacturing Services
13.58 HELP Therapeutics
13.59 Herophilus
- 13.59.1 Herophilus’ Approach
13.60 Hesperos, Inc.
- 13.60.1 Human-on-a-Chip®
13.61 Horizon Discovery
13.62 HUB Organoids BV
- 13.62.1 Products
13.63 iCamuno Biotherapeutics
- 13.63.1 Transient Naive Treatment (TNT)
13.64 iHeart Japan Corporation
- 13.64.1 Contract Services
13.65 IN8Bio
- 13.65.1 INB-500
13.66 InSphero
- 13.66.1 Products & Services
13.67 iPeace, Inc.
- 13.67.1 Products
- 13.67.2 Manufacturing Service
13.68 iPS Academia Japan, Inc.
- 13.68.1 Key Aspects of iPS Academia Japan, Inc.
13.69 IPS HEART
- 13.69.1 Proprietary Platform
  - 13.69.1.1 ISX9-CPC
  - 13.69.1.2 GIVI-MPC
13.70 iPSirius
- 13.70.1 iPVAC Technology
- 13.70.2 iPSirius’ Pipeline
13.71 iRegene Therapeutics
- 13.71.1 iReDita Platform
13.72 iXCells Biotechnologies
- 13.72.1 iXCells’ Core Services
- 13.72.2 Products
  - 13.72.2.1 Organoids
13.73 iXgene, Inc.
- 13.73.1 Technology
13.74 Jacobio Pharmaceuticals
- 13.74.1 Jacobio’s iPSC Collaboration with Hebecell
13.75 Kangstem Biotech
13.76 Kenai Therapeutics
- 13.76.1 Kenai’s iPSC Platform
- 13.76.2 Kenai’s Pipeline
13.77 Khloris Biosciences, Inc.
13.78 Kiji Therapeutics
13.79 Lambda Biologics GmbH
- 13.79.1 Organoid Services
13.80 Laverock Therapeutics
- 13.80.1 iPSC-derived Cell Therapies
13.81 Lineage Cell Therapeutics
13.82 Lonza
- 13.82.1 Key Contributions
13.83 Megakaryon Corporation
- 13.83.1 Technology
- 13.83.2 Megakaryons R&D Pipeline
13.84 Miltenyi Biotec, Inc.
- 13.84.1 Tools for Manual iPSC Workflows
- 13.84.2 Automated and Closed iPSC Manufacturing
13.85 Morphocell Technologies, Inc.
- 13.85.1 ReLiver
13.86 Myoridge Co. Ltd.
- 13.86.1 Products & Services
13.87 Ncardia
- 13.87.1 Products
- 13.87.2 Services
13.88 NeuCyte, Inc.
- 13.88.1 Technology
- 13.88.2 NeuCyte’s Services
13.89 Neukio Biotherapeutics
13.90 NEXEL
- 13.90.1 Organoids
- 13.90.2 iPSC Derived Cells
- 13.90.3 Instruments
- 13.90.4 NeXST (Next Xight Screening Test)
- 13.90.5 Disease Modeling
- 13.90.6 Cell Customization
- 13.90.7 Services
13.91 Okomera
- 13.91.1 Ocentra
13.92 Organovo Holdings, Inc.
- 13.92.1 Product Pipeline
13.93 Orizuru Therapeutics
13.94 Oxford StemTech
- 13.94.1 Services Offered
13.95 Parallel Bio
13.96 Pixl Bio, Ltd.
- 13.96.1 Platform
- 13.96.2 Products
  - 13.96.2.1 The pixStellate iPSC-derived Stellate Cells
  - 13.96.2.2 pixHep/pixStellate Co-Culture Models
  - 13.96.2.3 MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Models
  - 13.96.2.4 The pixHep A1ATD (Alpha-1 Antitrypsin Deficiency) Models
  - 13.96.2.5 The pixHep PFIC2 (Progressive Familial Intrahepatic Cholestasis Type 2) Model
  - 13.96.2.6 The pixHep UCD (Urea Cycle Disorder) Models (ASS1, and OTC)
13.97 Pluristyx, Inc.
- 13.97.1 FailSafe Cell System
- 13.97.2 iACT Stealth Cells™
- 13.97.3 Products
  - 13.97.3.1 PluriBank™
  - 13.97.3.2 PluriForm™ Kit
  - 13.97.3.3 PluriFreeze™ Cryopreservation System
  - 13.97.3.4 PluriKit™
- 13.97.4 iPSC Generation
- 13.97.5 Differentiated Cells
13.98 Porosome Therapeutics, Inc.
- 13.98.1 iPSC Derived Beta Cell T1D Therapy
13.99 Quell Therapeutics Ltd
- 13.99.1 Collaboration for iPSCs
13.100 Racthera Co., Ltd.
- 13.100.1 Amchepry®
- 13.100.2 Racthera’s Retinal Sheet (DSP-3077)
- 13.100.3 Racthera's Retinal pigment epithelial cells (HLCR011)
- 13.100.4 Racthera's Neural progenitor cells (SMP-0115)
13.101 Rege Nephro, Co., Ltd.
- 13.101.1 RN-032
13.102 Repairon GmbH
- 13.102.1 Technology
13.103 ReproCELL
- 13.103.1 Services
- 13.103.2 Product Offerings
- 13.103.3 ReproCELL’s Clinical Pipelines
13.104 Res Nova Biologics
13.105 Ricoh Biosciences, Inc.
- 13.105.1 Products
- 13.105.2 Ricoh’s iPSC-related Services
- 13.105.3 Ricoh’s Therapeutics Development Pipeline
13.106 Sampled
- 13.106.1 Services
13.107 Sana Biotechnology
13.108 Sarcio, Inc.
- 13.108.1 SEV-101
- 13.108.2 SEVA-101
13.109 SCG Cell Therapy, Pte. Ltd.
13.110 SereNeuro Therapeutics
13.111 Shinobi Therapeutics
13.112 STEMCELL Technologies
- 13.112.1 Services
13.113 StemCardia
- 13.113.1 Core Product & Technology
13.114 StemSight
- 13.114.1 StemSight’s Technology
13.115 Stemson Therapeutics
- 13.115.1 KeyProduct & Service Portfolio
13.116 Stimuliver
13.117 Sumitomo Pharma
13.118 Synthego
- 13.118.1 Core Capabilities
13.119 Telescope Therapeutics
- 13.119.1 Core Cellular & Technology Platforms
13.120 Tempo Bioscience
- 13.120.1 Products
13.121 Tenaya Therapeutics
- 13.121.1 Drug Development Capability
- 13.121.2 Disease Models
13.122 TGD Life Company Limited
- 13.122.1 R&D Services
13.123 Thermo Fisher Scientific Inc.
- 13.123.1 Key Contributions
13.124 Tolerance Bio
13.125 Trailhead Biosystems®
- 13.125.1 HD-DoE (high-dimensional design-of-experiments) technology
- 13.125.2 Trailhead’s Hematopoietic Progenitor Cells
- 13.125.3 hiPSC-derived Dopaminergic Neurons
- 13.125.4 hiPSC-derived Pancreatic Beta Cells
13.126 TreeFrog Therapeutics
- 13.126.1 C-Stem™
13.127 Vanqua Bio
- 13.127.1 Pipeline
13.128 Vascugen, Inc.
- 13.128.1 Core Technology & Approach
13.129 VCCT Inc.
- 13.129.1 VCCT’s Product Candidates
13.130 Vertex Pharmaceuticals
- 13.130.1 Key iPSC-Based Products & Programs
13.131 Vivodyne
- 13.131.1 Lab-Grown Organs
13.132 Yashraj Biotechnology, Ltd.
- 13.132.1 Products
  - 13.132.1.1 Induced Pluripotent Stem Cell (iPSC) Lines
  - 13.132.1.2 iPSC-Derived Cardiomyocytes (YBLiCardio)
  - 13.132.1.3 iPSC-Derived Hepatocytes Like Cells (YBLiHepato)

INDEX OF FIGURES

FIGURE 5.1: Rapid Growth of iPSC Publications in PubMed.gov
FIGURE 5.2: PubMed Published iPSC Papers on Pathophysiological Studies
FIGURE 5.3: PubMed Published iPSC Papers on Reprogramming Studies
FIGURE 5.4: PubMed Published Papers on iPSC Differentiation Studies
FIGURE 5.5: PubMed Published Papers on iPSC-based Drug Discovery
FIGURE 5.6: PubMed Published Papers on iPSC-based Cell Therapy
FIGURE 6.1: Number of iPSC Patents filed per Year, 2000-April 3, 2026
FIGURE 7.1: iPSC Clinical Trials by Study Designs
FIGURE 7.2: Therapeutic & Non-Therapeutic iPSC Clinical Trials
FIGURE 7.3: Non-Therapeutic iPSC Clinical Trials by Use
FIGURE 7.4: Percent Share of Diseases Targeted by Therapeutic Studies
FIGURE 7.5: iPSC Clinical Trials by Funder Type
FIGURE 7.6: Geographic Distribution of iPSC Clinical Trials
FIGURE 9.1: Roles of OSKM Factors in the Induction of iPSCs
FIGURE 9.2: Delivery Methods for Reprogramming Factors
FIGURE 11.1: Biomedical Applications of iPSCs
FIGURE 11.2: Potential of iPSCs in Toxicity Testing and Drug Screening
FIGURE 11.3: Relative Use of iPSC-Derived Cell Types used in Toxicity Testing Studies
FIGURE 12.1: Global Market for iPSCs by Geography, 2025-2034
FIGURE 12.2: Global Market for iPSCs by Market Segments
FIGURE 12.3: Global Market for iPSC-Related Reprogramming Technologies, 2026-2034
FIGURE 12.4: Global Market for iPSC-Derived Cell Types, 2025
FIGURE 12.5: Global Market for Manual & Automated iPSC Production Services, 2025
FIGURE 12.6: Market Share for Key Modules in iPSC Production, 2025
FIGURE 12.7: Market Shares of Products Utilized in iPSC Manufacturing, 2025
FIGURE 12.8: Percent Market Share of iPSC-Derived Cells by End-Use, 2025

INDEX OF TABLES

TABLE 3.1: Examples of iPSC-based Autologous & Allogeneic Products in Phase II
TABLE 3.2: Disease Areas Focused by iPSC-based Clinical Trials
TABLE 3.3: Companies Providing AI-Powered Automation Services
TABLE 3.4: Key Platforms used in Automatic iPSC Production
TABLE 4.1: Donor Selection and Screening Process
TABLE 4.2: Common Sources of Somatic Cells for Reprogramming into iPSCs
TABLE 4.3: Key Reprogramming Vectors used in iPSC Generation
TABLE 4.4: Methods of selecting iPSC Colonies after Reprogramming
TABLE 4.5: Examples of Differentiated Cell Types from iPSCs
TABLE 4.6: Examples of iPSC-Derived Organoids
TABLE 5.1: Landmark Publications in iPSC Research
TABLE 5.2: Rapid Growth of iPSC Publications in PubMed.gov
TABLE 5.3: Anticipated advancements in iPSC-based therapeutic applications
TABLE 5.4: Enhanced Disease Modeling and Drug Discovery
TABLE 5.5: Technological Innovations and Automation
TABLE 6.1: Number of Patents filed per year, 1993-April 3, 2026
TABLE 6.2: iPSC Patent Applications by Jurisdiction as of April 3, 2026
TABLE 6.3: Top 100 iPSC Patent Applicants as of April 3, 2026
TABLE 6.3: (CONTINUED)
TABLE 6.3: (CONTINUED)
TABLE 6.4: Top 100 Inventors of iPSC Patent Applications
TABLE 6.4: (Continued)
TABLE 6.4: (CONTINUED)
TABLE 6.5: Top 100 Owners of iPSC Patent Applications
TABLE 6.5: (CONTINUED)
TABLE 6.5: (CONTINUED)
TABLE 6.6: Legal Status of iPSC Patent Applications as of April 4, 2026
TABLE 6.7: Recently Granted iPSC Patents (2024-2026)
TABLE 6.8: Licensing Fees for iPSC Patents
TABLE 7.1: Late-Stage iPSC Clinical Trials & Progress
TABLE 7.2: Recruitment Status of iPSC Clinical Trials, 2023-2026
TABLE 7.3: Select Clinical Trials in Ocular Diseases
TABLE 7.4: Select Clinical Trials Focusing on CNS Disorders
TABLE 7.5: Select Clinical Trials Focusing on IPSC-Based Cardiomyocytes and Muscle Products
TABLE 7.6: Select Clinical Trials focusing on iPSC-Based in Immune and Blood Products
TABLE 7.7: Select Stromal Products in Clinical Trials
TABLE 7.8: iPSC-based Clinical Trials by Phase of Study
TABLE 7.9: Geographic Distribution of iPSC Clinical Trials
TABLE 7.10: Key Future Directions of iPS-Based Trials
TABLE 8.1: M&A Deals signed in iPSC Sector, 2023-2026
TABLE 8.2: Collaboration/Partnership & Licensing Deals in iPSC Sector, 2023-2026
TABLE 8.3: Venture Capital Funding Raised by iPSC Companies, 2021-April 2026
TABLE 9.1: Core Reprogramming Factors (OSKM)
TABLE 9.2: Top Companies offering iPSC Reprogramming Services
TABLE 9.3: Key Combination of Factors for Direct Reprogramming
TABLE 9.4: Companies Involved in Direct Reprogramming Services
TABLE 9.5: Efficacy of iPSC Reprogramming Methods
TABLE 9.6: Companies offering CRISPR/Cas9 Services for iPSC Generation
TABLE 9.7: Key Companies developing iPSC-Derived Organoids
TABLE 9.8: Key Companies developing iPSC-Derived Cardiac Tissue Sheets
TABLE 9.9: Companies developing iPSC-Derived RPE Sheets
TABLE 10.1: Key Human iPSC Banks
TABLE 10.2: iPSC Lines available with EBiSC
TABLE 10.3: Price List for CiRA’s Clinical Grade iPSCs
TABLE 10.4: Cell Types Banked by WiCell
TABLE 10.5: iPS Cell Lines in Coriell’s Collection
TABLE 10.6: Cell Sources & Reprogramming Methods in iPSC Banks
TABLE 10.7: Ownership & Funding for iPSC Banks
TABLE 11.1: Top Providers of iPSC Research Products for Researchers
TABLE 11.2: Commonly used iPSC Reprogramming Kits
TABLE 11.3: Commonly used Culture Media and Reagents in Research
TABLE 11.4: Key Companies offering iPSC-Derived Cell Types for Research
TABLE 11.5: Companies providing iPSC-Derived 3D Organoids for Research
TABLE 11.6: Companies offering iPSCs-related Specialized Services
TABLE 11.6: (CONTINUED)
TABLE 11.7: Key Companies involved in Patient-Specific Disease Modeling
TABLE 11.8: Companies offering iPSC-Derived Cardiomyocytes for Drug Discovery
TABLE 11.9: Cardiovascular Drugs Tested in iPSC Models
TABLE 11.10: Companies offering iPSC-derived Neuronal Cells for Drug Discovery
TABLE 11.11: Drugs Tested for Neurological Diseases using iPSCs
TABLE 11.12: Companies offering iPSC-Derived RPEs
TABLE 11.13: Drugs Tested for Ocular Diseases using iPSC Lines
TABLE 11.14: Companies developing iPSCs to Discover Drugs for Metabolic Diseases
TABLE 11.15: Drugs Tested in iPSCs for Metabolic Diseases
TABLE 11.16: Companies developing iPSCs to Discover Drugs for Blood Disorders
TABLE 11.17: Drugs Tested for Blood Disorders using iPSCs
TABLE 11.18: Key Companies offering HTS Services using iPSCs
TABLE 11.19: Companies offering Toxicity Testing Services using iPSCs
TABLE 11.20: Drugs Tested for their Toxicity using iPSC Lines
TABLE 11.21: Companies using iPSCs in Personalized Medicine and Genomic Studies
TABLE 11.22: Key Applications of iPSC-Derived Cells in Cell Therapy
TABLE 11.23: Key Players & Focus Areas in iPSC-Based Cell Therapy
TABLE 11.24: Key Therapeutic Targets in iPSC-Based Cell Therapy Clinical Trials
TABLE 11.25: Select iPSC-Based Cell Therapy Clinical Trials
TABLE 11.26: Major Conservation Initiatives & Species
TABLE 11.27: Companies developing Cultured Meat using iPSC-Derived Cells
TABLE 12.1: Global Market for iPSCs by Geography, 2025-2034
TABLE 12.2: Global Market for iPSCs by Market Segments
TABLE 12.3: Global Market for iPSC-Related Reprogramming Technologies, 2026-2034
TABLE 13.1: AcceGen’s Pipeline Product Candidates
TABLE 13.2: Aspen’s Clinical Pipeline
TABLE 13.3: BlueRock’s Pipeline Focusing on New Therapies
TABLE 13.4: BrightPath’s Product Pipeline
TABLE 13.5: Cartheric’s R&D Pipeline of Allogeneic Products
TABLE 13.6: Celregen’s Key iPSC Product Candidates
TABLE 13.7: Cellectis’ Main Product Candidates
TABLE 13.8: Celregen’s Product Pipeline
TABLE 13.9: Century Therapeutics’ Pipeline Overview
TABLE 13.10: Cynata’s Clinical Pipeline
TABLE 13.11: Factor Bioscience’s iPSC-Based Clinical Trials
TABLE 13.12: Fate Therapeutics’ Pipeline Overview
TABLE 13.13: Gameto’s Pipeline
TABLE 13.14: Greenstone’s Pipeline
TABLE 13.15: Healios’ Research and Development Status
TABLE 13.16: Hebecell’s Pipelines
TABLE 13.17: HELP’s R&D Pipeline
TABLE 13.18: Herophilus’ Pipeline Development using Organoids
TABLE 13.19: Key Available Organoid Types with HUB
TABLE 13.20: iCamuno’s Product Pipeline
TABLE 13.21: IPS HEART’s Pipeline
TABLE 13.22: iPSirius’ Pipeline
TABLE 13.23: iRegene’s Pipelines
TABLE 13.24: Kenai’s Pipeline
TABLE 13.25: Khloris’ iPSC Product Development Stages and Diseases Addressed
TABLE 13.26: Kiji’s R&D Pipeline
TABLE 13.27: Laverock’s Pipeline
TABLE 13.28: Pipeline from Lineage Cell Therapeutics
TABLE 13.29: Megakaryon’s R&D Pipeline
TABLE 13.30: Morphocell’s Pipeline
TABLE 13.31: ReproCELL’s Clinical Pipelines Currently under Development
TABLE 13.32: Ricoh’s Therapeutics Development Pipeline
TABLE 13.33: Sana’s Product Candidates
TABLE 13.34: Sumitomo’s iPSC Products in Development
TABLE 13.35: Vanqua Bio’s Pipeline
TABLE 13.36: Vascugen’s Product Pipeline
TABLE 13.37: VCCT’s Pipeline